Study of Biological Effect of Tarceva (OSI-774) for Patients Stricken by ENT Epidermoid Carcinoma

Inclusion Criteria:

* Neck and head epidermoid carcinoma histologically proved. Patient with an ENT epidermoid tumor can be included in the study if this relapse is located in an area not irradiated yet.
* At least tumor classified T2NXM0
* Patient who can be picked up in a first surgery with a curative purpose or who must have a necessity's surgery (cervical curettage for voluminous adenopathies before radiotherapy)
* Patient without clinical or radiological sign of metastatic disease
* Good general status (OMS ≤ 2)
* Patient able to ingest food.
* Age ≥ 18 years
* Well-informed written consent, signed by the patient.
* Patient with sickness benefit

Exclusion Criteria:

* Patient with relapse ever treated by radiotherapy
* Other prospective study's participation
* Recent and massive digestive haemorrhage
* Medical contra-indication like main general status alteration, uncontrolled serious infectious disease, main uncontrolled metabolic anomaly ongoing.
* Pre-existent pulmonary pathology (BPCO, pleurisy, lymphangitis, interstitial syndrome)
* Severe cardiac pathology (stage 3 or 4 cardiac insufficiency, unstable angina pectoris, uncontrolled arrhythmia, myocardium's infarction antecedent during the year that precede the inclusion.
* Ophthalmic pathology antecedent concerning the ocular surface or lens-carrier
* Concomitant administration, by local or general tract, of drug responsible for ocular drought or which could delay the epithelial cicatrization
* Less than 1000 polynuclear neutrophil leucocytes or less than 75000 blood-platelets at inclusion
* Bilirubin at higher concentration than one point five times the normal
* Renal insufficiency (glomerular filtration flow ≤ 40 ml/min)calculated in accordance with Cockroft's formula
* Tacking of Beta blockers, amiodarone, NSAIDs, bleomycin, just before or during the study
* Pregnant or nursing women
* Patient under guardianship or trusteeship.